We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Global Hematology Diagnostic Devices and Equipment Market to Reach USD 2.35 Billion by 2022

By LabMedica International staff writers
Posted on 03 Jan 2020
Print article
Image: Analyticon Coagulyzer 100 (Photo courtesy of Analyticon)
Image: Analyticon Coagulyzer 100 (Photo courtesy of Analyticon)
The global hematology diagnostic devices and equipment market was valued at about USD 1.9 billion in 2018 and is projected to grow to at a CAGR of 5.5% to USD 2.35 billion in 2022. The market growth is driven mainly by an increase in the use of hematology diagnostic devices due to the rising prevalence of blood disorders which affect millions of people each year across the world, irrespective of age, race, and sex.

These are the latest findings of The Business Research Company (London, UK), a market research and intelligence company.

Despite its potential for rapid growth, the hematology diagnostic devices market is constrained by stringent regulation policies. Currently, the FDA regulates class I, class II, and class III hematology devices. Class I hemostasis devices are exempt from premarket notification requirements and are used only for general control. Regulations for class II devices are exempt from premarket notification requirements and they can be used for special controls. Class III is the most stringent category as it requires premarket approval (PMA).

Companies in the hematology diagnostic devices market are increasingly investing in automation technology. The advancements in automation technology are driving the demand for hematology analyzers and will continue to reduce the errors caused by manual practices in diagnostic centers. However, product recall is one of the major problems being faced by companies in the hematology diagnostic devices market and can negatively affect market growth.

Related Links:
The Business Research Company


Print article

Channels

Molecular Diagnostics

view channel
Image: Blood smear from a P. falciparum culture: several red blood cells have ring stages inside them while close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)

Panel of MicroRNAs Differentiates Uncomplicated and Severe Malaria in Children

MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of severe malaria. MiRNAs comprise a class of about 20 n... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.